News & Events

What’s new with DiaSorin Molecular and our upcoming conferences

News



DiaSorin Molecular Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2, including the India B.1.617

Cypress, Calif. (May 21, 2021) – DiaSorin Molecular LLC announced today that it has released the Simplexa™ SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction….

DiaSorin Molecular Receives Additional BARDA Funding in Support of Submitting the Simplexa™ COVID-19 Direct and the Simplexa™ COVID-19 & Flu A/B Direct kits for FDA 510(k) Clearance

Cypress, California (USA) – January 13, 2021 – DiaSorin Molecular LLC, a subsidiary of DiaSorin S.p.A. (FTSE MIB:DIA), announced today that it has received additional federal funding from the Biomedical Advanced Research and Development Authority (BARDA),…

DiaSorin Molecular’s Simplexa™ COVID-19 Direct Molecular Test CE Marked for Saliva Specimens

Cypress, Calif. (September 17, 2020) – DiaSorin Molecular LLC announced today that it has attained CE Marking for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay….

Upcoming Events

Event center

DiaSorin Molecular Event Center provides high quality Continuing Education programs for laboratory professionals. Our Web-based educational seminars are designed to present current, relevant information on a number of infectious disease and other related topics. Speakers are selected for their expertise in laboratory diagnostics and excellent presentation skills.

VISIT OUR EVENT CENTER